The Food and Drug Administration says it will begin offering faster reviews to new medicines that align with Trump administration priorities for Americans' health. The new program announced Tuesday aims to review select drugs in just one to two months. It was announced by FDA Commissioner Marty Makary, who has promised “faster cures” since arriving at the agency in April. Makary says the FDA will begin offering special vouchers to drugmakers who are “aligned with U.S. national priorities.” The FDA already has a variety of programs designed to speed up drug reviews, but they all have fairly strict medical criteria.
